Clinical trial
A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With…
NCT00483834 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00483834 |
|---|---|
| Title | A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer |
| Official title | A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Irinotecan, Capecitabine |
| Enrollment | 50 |
| Start date | Dec 1, 2006 |
| Primary completion | Jul 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | Jun 7, 2007 |
| Last update posted | Feb 15, 2019 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: